title: Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection.
abstract: BACKGROUND
  Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with neutropenia. Two severe complications with poor outcome can be observed after apparently successful IPA medical treatment: severe hemoptysis and IPA relapse during subsequent cytotoxic treatments. Early surgical therapy has not been considered routinely in the management of localized IPA.
  
  
  METHODS
  Six consecutive patients (four women, two men; median age, 52 years) with localized cavitating IPA diagnosed during chemotherapy-induced aplasia were treated with early surgical resection after hematologic recovery.
  
  
  RESULTS
  All patients received a lobectomy. Surgery was uneventful. This procedures allows patients to proceed with further intensive chemotherapy and/or bone marrow transplantation without IPA reactivation.
  
  
  CONCLUSIONS
  For selected patients, surgical resection of localized IPA with unique cavitating lesion, which prevents hemoptysis and IPA recurrence and allows for subsequent cytotoxic treatment, may be recommended.
authors.affiliation: Department of Hematology, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: J R
authors.initials: JR
authors.lastname: Zahar
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: O
authors.initials: O
authors.lastname: Baron
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: D
authors.initials: D
authors.lastname: Wu
authors.forename: P
authors.initials: P
authors.lastname: Germaud
authors.forename: P
authors.initials: P
authors.lastname: Despins
authors.forename: A Y
authors.initials: AY
authors.lastname: Delajartre
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D011013:Pneumonectomy; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000666:Amphotericin B